Mechanistically, the study uncovered a novel interaction between PPP2CB and LOX-1 and demonstrated the downstream activation of the MAPK/ERK pathway, contributing new insights into the intracellular regulatory network of dyslipidemia-induced atherosclerosis. The gene discussed is PPP2CB; the disease is metabolic syndrome.